89bio, Inc. Announces Agreement to be Acquired by Roche
September 18, 2025 01:02 ET | Source: 89bio, Inc. – 89bio stockholders…
RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance…
Theratechnologies enters into Definitive Agreement to be Acquired by CBBiotechnology, an Affiliate of Future Pak
Offer of US$3.01 in cash plus one contingent value right for potential…
HUDA BEAUTY RECLAIMS FULL OWNERSHIP AS AN INDEPENDENT BEAUTY BRAND
DUBAI, UAE, June 3, 2025 /PRNewswire/ -- Huda Beauty, the globally renowned…
